Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck & Co.'s Keytruda, BioLineRx's Motixafortide Combine To Good Effect In Pancreatic Cancer

Keytruda Also Shown To Work With Eisai's Lenvima In Endometrial Cancer

Executive Summary

BioLineRx's Phase IIa study of Keytruda/motixafortide/chemo showed improvements in overall and progression-free survival compared with historical data.

You may also be interested in...



Merck’s Keytruda Works With Lenvima In Renal Cancer, But Not With Yervoy In Lung Cancer

Merck’s PD-1 inhibitor combined with Lenvima offered benefit in RCC, but use with Bristol’s Yervoy in metastatic NSCLC showed no benefit compared to Keytruda monotherapy.

Interview: BioLineRx Pushes Ahead In Pancreatic Cancer

The Israeli group is confident that its CXCR4 antagonist has potential as a platform molecule for a range of cancers at various stages of disease.

Twin Presentations Position Merck, GSK PD-1 Inhibitors As Endometrial Cancer Rivals

Merck’s Keytruda may nevertheless have the stronger market position given its broader and stronger labeling in second-line endometrial cancer and strong position in women’s oncology overall.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC143505

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel